Randomized Controlled Trials Versus Real World Evidence: Neither Magic Nor Myth

Area of Science:

• Pharmaceutical Sciences
• Biotechnology
• Medical Research

Background:

• Modern therapeutics encompass diverse modalities like biologics, cell, and gene therapies, often targeting rare diseases or individual patients.
• This heterogeneity contrasts with the blockbuster drugs of the past, necessitating re-evaluation of traditional definitions and approaches.

Purpose of the Study:

• To analyze the impact of evolving drug types on clinical use and evidence generation strategies.
• To discuss the limited applicability of 20th-century evidence generation lessons to 21st-century medicines.
• To propose an integrated approach for evaluating novel therapeutics.

Main Methods:

• Review of trends in drug development and regulatory science.
• Analysis of the evolving definitions of "drugs" and "target populations."
• Discussion on the complementary roles of randomized controlled trials (RCTs) and real-world evidence (RWE).

Main Results:

• 21st-century medicines, including personalized treatments, require novel evidence generation frameworks.
• The dichotomy of RCTs versus RWE is outdated; integration is key for assessing safety and effectiveness.
• Detecting small treatment effects in precision medicine may challenge current RCT and RWE methodologies.

Conclusions:

• Traditional evidence generation paradigms are insufficient for novel therapeutics.
• An integrated RCT and RWE approach is crucial for evaluating modern medicines.
• Future research must address methodologies for assessing subtle treatment effects in precision medicine.